Drugs that contain Dalbavancin Hydrochloride
1. List of Dalvance drug patents
DALVANCE's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143212 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months from now) | |
| US7119061 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months from now) | |
| US7115564 | ALLERGAN | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(5 months from now) | |
| US6900175 | ALLERGAN | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(4 years from now) | |
Do you want to check out DALVANCE patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 23, 2019 |
| New Patient Population (NPP) | Jul 22, 2024 |
| Generating Antibiotic Incentives Now (GAIN) | May 23, 2024 |
NCE-1 date: 2023-05-24
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
DALVANCE family patents
28
United States
5
Japan
5
Australia
4
Korea, Republic of
3
Hong Kong
3
China
3
Russia
3
Israel
3
South Africa
2
Canada
2
Norway
2
New Zealand
2
Mexico
2
European Union
1
Spain
1
Denmark
1
Brazil
1
Singapore
1
Portugal
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic